Are there any targeted therapies for IDH2-mutant Cancers?
Yes, the development of targeted therapies for IDH2-mutant cancers has been a significant advancement. One such drug is enasidenib, an IDH2 inhibitor approved for the treatment of relapsed or refractory AML. This drug works by inhibiting the mutant IDH2 enzyme, thereby reducing the levels of 2-HG and restoring normal cellular function.
